Key result
Each ten percent increase in sleep apnea variability linked to ~89% higher persistent device-detected AF risk.
Why the study?
Does high night-to-night variability in sleep apnea increase the risk of persistent device-detected atrial fibrillation and greater AF burden in pacemaker patients?
Does high night-to-night variability in sleep apnea increase the risk of persistent device-detected atrial fibrillation and greater AF burden in pacemaker patients?
Night-to-night variability in sleep apnea, continuously monitored via pacemaker thoracic impedance, is significantly associated with the persistence and burden of device-detected atrial fibrillation.
Supports assessing sleep apnea variability to predict persistent AF in pacemaker patients; leaves open causality and therapeutic potential.
Using pacemaker-derived thoracic impedance monitoring, sleep apnea severity and its night-to-night variability can be continuously tracked in patients with implanted cardiac devices. In the prospective ACaSA study, 171 pacemaker patients without permanent atrial fibrillation at baseline were followed for a median of 539 days. During an initial 28-night run-in period free of atrial fibrillation, baseline night-to-night variability of the respiratory disturbance index (RDI) was quantified as the coefficient of variation. Patients were subsequently monitored for the onset of persistent device-detected atrial fibrillation (DDAF, ≥ 7 days) and cumulative DDAF burden. Median RDI variability was 38.7% (IQR 29.9%-47.6%), and 35 patients (20.5%) had high variability (≥ 50%). Over follow-up, 17 patients (9.9%) developed persistent DDAF. Each 10% increase in RDI variability was associated with a significantly higher risk of persistent DDAF (adjusted HR 1.89, 95% CI 1.26-2.84; p = 0.002). Patients with high variability also carried a greater cumulative DDAF burden compared to those with low variability (9.6% vs. 1.9%, p = 0.016). These results suggest that the dynamic instability of sleep apnea, reflected by night-to-night variability, is associated with DDAF persistence and burden. Continuous long-term monitoring through pacemaker systems offers a novel approach for risk stratification and may open opportunities for more personalised management strategies.
No takes yet. Share an insight, caveat, or question.
Spitaler et al. (2026) studied this question. Each 10% increase in night-to-night sleep apnea variability increased risk of persistent device-detected atrial fibrillation by 89% (HR 1.89, p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: